Improved efficacy of tumor-targeted anticancer therapy and alleviation of side effects by H<sub>2</sub>O<sub>2</sub>-responsive polymeric prodrug nanoparticles
발표자
()
초록
내용
Anticancer therapy using drug delivery has been widely studied to increase therapeutic efficiency and alleviate off-target toxicity of chemotherapeutic drugs. However, the low drug loading capacity, delivery-related toxicity, and premature drug release remain to be solved. To overcome these problems, we developed anticancer polymeric prodrug (pHU) that is activated by pathological characteristics of tumor and exhibits therapeutic effects. T-pHUD, nanoparticles loaded with doxorubicin (DOX) and surface-decorated with taurodeoxycholic acid, target p-selectin in cancer cells and release hydroxybenzyl alcohol, ursodeoxycholic acid and DOX in an excessive H2O2 of tumor. The anticancer activity of T-pHUD was studied using cell culture model and A549 xenograft model. T-pHUD preferentially accumulated in tumor showed synergistic activity of pHU and DOX and prevented cardio- and hepatotoxicity. Based on these, we anticipate that T-pHUD hold translational potential as a tumor targeting nanomedicine.